New study tracks pancreatic cancer screening in gene mutation carriers

NCT ID NCT02478892

Recruiting now Knowledge-focused Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study follows 200 people with inherited mutations in BRCA1/2, ATM, or PALB2 genes who are already undergoing regular pancreatic cancer screening with endoscopic ultrasound or MRI. Researchers will track how often these imaging tests find pre-cancerous or cancerous lesions. The goal is to see if routine screening is feasible and how common these lesions are in this high-risk group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could show that regular screening helps catch pancreatic cancer early in people with certain gene mutations, potentially improving survival.
What could go wrong: This is an early observational study, not a treatment trial. It may not prove that screening saves lives, and results may not apply to all high-risk groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Abramson Cancer Center of the University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19004, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.